ArticleOncology letters2018
Values of miR-34a and miR-218 expression in the diagnosis of cervical cancer and the prediction of prognosis.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- MicroRNAs: Novel clinical biomarkers for cancer radiotherapy (Review).Molecular medicine reports · 2025Review
- E7HPV16 Oncogene and 17beta-Estradiol Stress, Promotes Oncogenic microRNA Expression Patterns, Cell Proliferation and Cervical Intraepithelial Neoplasia 1.Cell biochemistry and function · 2025Article
- Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment.Cancer medicine · 2023Review
- miR-218-5p/RUNX2 Axis Positively Regulates Proliferation and Is Associated with Poor Prognosis in Cervical Cancer.International journal of molecular sciences · 2022Article
- Cervical Cancer Imaging Features Associated WithFrontiers in neurology · 2022Article
- Overexpression of miR-3653 is Associated with HPV Infection and Serves as a Biomarker in Patients with Cervical Cancer.International journal of women's health · 2022Article
- Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma.American journal of translational research · 2021Article
- MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer.Journal of clinical medicine · 2020Review
- Roles of MicroRNA-34a in Epithelial to Mesenchymal Transition, Competing Endogenous RNA Sponging and Its Therapeutic Potential.International journal of molecular sciences · 2019Review
- Expression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance.Cancer biomarkers : section A of Disease markers · 2019Article
- Identification of a Novel Long Non-coding RNA,Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression levels of microribonucleic acid 34a (miR-34a) and miR-218 in the serum and tumor tissues of patients with cervical cancer were investigated to explore their relationship with the diagnosis of cervical cancer. Fifty patients with cervical cancer were selected, and 30 normal patients were selected as the control group. The expression levels of miR-34a and miR-218 were detected by quantitative real-time polymerase chain reaction. The relationship between the expression of miR-34a and miR-218 was analyzed using Pearson's correlation coefficient, and the receiver operating characteristic (ROC) curve was plotted for the analysis of values of the expression of miR-34a and miR-218. The correlation of the expressions of miR-34a and miR-218 in the serum with pathological parameters and the prognosis was analyzed. The expression levels of miR-34a and miR-218 in cervical cancer patients were significantly lower than those in normal patients. The ROC curve showed the area under curve (AUC) of miR-34a was 0.893, and miR-218 was 0.794. The low expression of miR-34a in patients with cervical cancer was correlated with the degree of tumor differentiation, lymph node metastasis and the International Federation of Gynecology and Obstetrics staging. The low expression of miR-218 was related to the degree of differentiation as well as invasion and metastasis. The 5-year overall survival rate of patients was 66%, and the low expression of miR-34a and miR-218 indicated a worse survival prognosis. The low expression of miR-34a in patients with cervical cancer is related to the degree of tumor differentiation as well as invasion and metastasis, and the low expression of miR-218 is related to the degree of tumor differentiation, invasion and metastasis and clinical staging. miR-34a and miR-218 in the serum can be used as markers for the diagnosis of cervical cancer and reference indicators for the evaluation of prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.